Ubidecarenone
As of the edition of 20 October 2026, Ubidecarenone is a small molecule: marketed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Small molecule
- Brand name
- Bio-Qinon Q10
- Approvals on record
- 6 in 6 regions
- Holder of the most recent approval
- Sidefarma - Sociedade Industrial De Expansão Farmacêutica, S.A.; 4 holders in all
- Registered trials
- 60, 7 stopped early
- Disease areas
- Nervous system; Heart and blood vessels; Cancer; Nutrition and metabolism; Skin and connective tissue; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 14 | 7 | 4 | 1 |
| Phase 1 | 8 | 4 | 2 | 1 |
| Phase 2 | 22 | 16 | 3 | 3 |
| Phase 3 | 8 | 3 | 1 | 1 |
| Phase 4 | 8 | 4 | 1 | 1 |
| All trials | 60 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Solvay Pharmaceuticals | Lead sponsor of trials | 2003 to now |
| BPGbio | Lead sponsor of trials | 2008 to now |
| PharmEvo Pvt | Lead sponsor of trials | 2017 to now |